Is PHIO or HOWL more profitable?

Phio Pharmaceuticals' return on equity of -87.41% beat Werewolf Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Phio Pharmaceuticals N/A -87.41% -79.76% Werewolf Therapeutics N/A -166.99% -59.88%

Does the media favor PHIO or HOWL?

In the previous week, Phio Pharmaceuticals had 1 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 2 mentions for Phio Pharmaceuticals and 1 mentions for Werewolf Therapeutics. Phio Pharmaceuticals' average media sentiment score of 0.33 beat Werewolf Therapeutics' score of 0.00 indicating that Phio Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phio Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Werewolf Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer MCRB or PHIO?

In the previous week, Phio Pharmaceuticals had 1 more articles in the media than Seres Therapeutics. MarketBeat recorded 2 mentions for Phio Pharmaceuticals and 1 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 0.94 beat Phio Pharmaceuticals' score of 0.33 indicating that Seres Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seres Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Phio Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, PHIO or MREO?

Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Phio Pharmaceuticals N/A N/A -$8.70M -$1.29 N/A Mereo BioPharma Group N/A N/A -$41.88M -$0.04 N/A

Is PHIO or MREO more profitable?

Mereo BioPharma Group's return on equity of -74.82% beat Phio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Phio Pharmaceuticals N/A -87.41% -79.76% Mereo BioPharma Group N/A -74.82% -64.28%

Does the media prefer PHIO or MREO?

In the previous week, Phio Pharmaceuticals had 1 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 2 mentions for Phio Pharmaceuticals and 1 mentions for Mereo BioPharma Group. Phio Pharmaceuticals' average media sentiment score of 0.33 beat Mereo BioPharma Group's score of 0.00 indicating that Phio Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phio Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mereo BioPharma Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor PHIO or MGX?

In the previous week, Phio Pharmaceuticals had 1 more articles in the media than Metagenomi. MarketBeat recorded 2 mentions for Phio Pharmaceuticals and 1 mentions for Metagenomi. Phio Pharmaceuticals' average media sentiment score of 0.33 beat Metagenomi's score of 0.00 indicating that Phio Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phio Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Metagenomi 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PHIO or ATNM more profitable?

Phio Pharmaceuticals' return on equity of -87.41% beat Actinium Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Phio Pharmaceuticals N/A -87.41% -79.76% Actinium Pharmaceuticals N/A -100.85% -47.89%

Does the media refer more to PHIO or ATNM?

In the previous week, Phio Pharmaceuticals had 1 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 2 mentions for Phio Pharmaceuticals and 1 mentions for Actinium Pharmaceuticals. Actinium Pharmaceuticals' average media sentiment score of 1.26 beat Phio Pharmaceuticals' score of 0.33 indicating that Actinium Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phio Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Actinium Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Phio Pharmaceuticals (PHIO) Competitors

$1.00 -0.02 (-1.86%)

As of 11:46 AM Eastern

Compare

PHIO vs. HOWL, MCRB, MREO, MGX, and ATNM

Should you buy Phio Pharmaceuticals stock or one of its competitors? Phio Pharmaceuticals's main competitors and comparable companies include Werewolf Therapeutics (HOWL), Seres Therapeutics (MCRB), Mereo BioPharma Group (MREO), Metagenomi (MGX), and Actinium Pharmaceuticals (ATNM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Phio Pharmaceuticals compare to Werewolf Therapeutics?

Phio Pharmaceuticals (NASDAQ:PHIO) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

Phio Pharmaceuticals' return on equity of -87.41% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phio Pharmaceuticals	N/A	-87.41%	-79.76%
Werewolf Therapeutics	N/A	-166.99%	-59.88%

Phio Pharmaceuticals has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market. Comparatively, Werewolf Therapeutics has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market.

57.3% of Phio Pharmaceuticals shares are owned by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are owned by institutional investors. 3.5% of Phio Pharmaceuticals shares are owned by company insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Phio Pharmaceuticals has higher earnings, but lower revenue than Werewolf Therapeutics. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.29	N/A
Werewolf Therapeutics	$21M	2.27	-$60.82M	-$0.76	N/A

In the previous week, Phio Pharmaceuticals had 1 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 2 mentions for Phio Pharmaceuticals and 1 mentions for Werewolf Therapeutics. Phio Pharmaceuticals' average media sentiment score of 0.33 beat Werewolf Therapeutics' score of 0.00 indicating that Phio Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phio Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Werewolf Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Phio Pharmaceuticals presently has a consensus price target of $14.00, suggesting a potential upside of 1,268.52%. Werewolf Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 308.58%. Given Phio Pharmaceuticals' higher probable upside, equities analysts plainly believe Phio Pharmaceuticals is more favorable than Werewolf Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Summary

Phio Pharmaceuticals and Werewolf Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Phio Pharmaceuticals compare to Seres Therapeutics?

Seres Therapeutics (NASDAQ:MCRB) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

In the previous week, Phio Pharmaceuticals had 1 more articles in the media than Seres Therapeutics. MarketBeat recorded 2 mentions for Phio Pharmaceuticals and 1 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 0.94 beat Phio Pharmaceuticals' score of 0.33 indicating that Seres Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seres Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Phio Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are owned by institutional investors. 5.2% of Seres Therapeutics shares are owned by insiders. Comparatively, 3.5% of Phio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Seres Therapeutics has a beta of 0.21, meaning that its share price is 79% less volatile than the broader market. Comparatively, Phio Pharmaceuticals has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market.

Seres Therapeutics has higher revenue and earnings than Phio Pharmaceuticals. Seres Therapeutics is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	46.31	$5.70M	-$2.43	N/A
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.29	N/A

Seres Therapeutics presently has a consensus price target of $17.00, indicating a potential upside of 367.03%. Phio Pharmaceuticals has a consensus price target of $14.00, indicating a potential upside of 1,268.52%. Given Phio Pharmaceuticals' higher possible upside, analysts clearly believe Phio Pharmaceuticals is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Phio Pharmaceuticals has a net margin of 0.00% compared to Seres Therapeutics' net margin of -1,192.94%. Phio Pharmaceuticals' return on equity of -87.41% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%
Phio Pharmaceuticals	N/A	-87.41%	-79.76%

Summary

Seres Therapeutics beats Phio Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Phio Pharmaceuticals compare to Mereo BioPharma Group?

Phio Pharmaceuticals (NASDAQ:PHIO) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.29	N/A
Mereo BioPharma Group	N/A	N/A	-$41.88M	-$0.04	N/A

57.3% of Phio Pharmaceuticals shares are held by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are held by institutional investors. 3.5% of Phio Pharmaceuticals shares are held by company insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Phio Pharmaceuticals presently has a consensus target price of $14.00, suggesting a potential upside of 1,268.52%. Mereo BioPharma Group has a consensus target price of $1.67, suggesting a potential upside of 409.68%. Given Phio Pharmaceuticals' higher possible upside, analysts clearly believe Phio Pharmaceuticals is more favorable than Mereo BioPharma Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Mereo BioPharma Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

In the previous week, Phio Pharmaceuticals had 1 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 2 mentions for Phio Pharmaceuticals and 1 mentions for Mereo BioPharma Group. Phio Pharmaceuticals' average media sentiment score of 0.33 beat Mereo BioPharma Group's score of 0.00 indicating that Phio Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phio Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mereo BioPharma Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Phio Pharmaceuticals has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market.

Mereo BioPharma Group's return on equity of -74.82% beat Phio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phio Pharmaceuticals	N/A	-87.41%	-79.76%
Mereo BioPharma Group	N/A	-74.82%	-64.28%

Summary

Mereo BioPharma Group beats Phio Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Phio Pharmaceuticals compare to Metagenomi?

Phio Pharmaceuticals (NASDAQ:PHIO) and Metagenomi (NASDAQ:MGX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

Phio Pharmaceuticals presently has a consensus price target of $14.00, suggesting a potential upside of 1,268.52%. Metagenomi has a consensus price target of $6.00, suggesting a potential upside of 430.97%. Given Phio Pharmaceuticals' higher probable upside, research analysts clearly believe Phio Pharmaceuticals is more favorable than Metagenomi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Phio Pharmaceuticals has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market. Comparatively, Metagenomi has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market.

57.3% of Phio Pharmaceuticals shares are owned by institutional investors. 3.5% of Phio Pharmaceuticals shares are owned by company insiders. Comparatively, 12.5% of Metagenomi shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Phio Pharmaceuticals had 1 more articles in the media than Metagenomi. MarketBeat recorded 2 mentions for Phio Pharmaceuticals and 1 mentions for Metagenomi. Phio Pharmaceuticals' average media sentiment score of 0.33 beat Metagenomi's score of 0.00 indicating that Phio Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phio Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Metagenomi	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Phio Pharmaceuticals has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -63.65% beat Phio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phio Pharmaceuticals	N/A	-87.41%	-79.76%
Metagenomi	-384.61%	-63.65%	-44.52%

Phio Pharmaceuticals has higher earnings, but lower revenue than Metagenomi. Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.29	N/A
Metagenomi	$13.56M	3.15	-$87.87M	-$2.49	N/A

Summary

Phio Pharmaceuticals and Metagenomi tied by winning 8 of the 16 factors compared between the two stocks.

How does Phio Pharmaceuticals compare to Actinium Pharmaceuticals?

Phio Pharmaceuticals (NASDAQ:PHIO) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

57.3% of Phio Pharmaceuticals shares are owned by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 3.5% of Phio Pharmaceuticals shares are owned by company insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Phio Pharmaceuticals' return on equity of -87.41% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phio Pharmaceuticals	N/A	-87.41%	-79.76%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

In the previous week, Phio Pharmaceuticals had 1 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 2 mentions for Phio Pharmaceuticals and 1 mentions for Actinium Pharmaceuticals. Actinium Pharmaceuticals' average media sentiment score of 1.26 beat Phio Pharmaceuticals' score of 0.33 indicating that Actinium Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phio Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Actinium Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Phio Pharmaceuticals has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market. Comparatively, Actinium Pharmaceuticals has a beta of 0.05, suggesting that its stock price is 95% less volatile than the broader market.

Phio Pharmaceuticals presently has a consensus target price of $14.00, indicating a potential upside of 1,268.52%. Actinium Pharmaceuticals has a consensus target price of $5.00, indicating a potential upside of 318.41%. Given Phio Pharmaceuticals' higher possible upside, equities analysts plainly believe Phio Pharmaceuticals is more favorable than Actinium Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Phio Pharmaceuticals has higher earnings, but lower revenue than Actinium Pharmaceuticals. Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.29	N/A
Actinium Pharmaceuticals	$35.09M	1.07	-$48.82M	$0.36	3.32

Summary

Phio Pharmaceuticals beats Actinium Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Get Phio Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHIO vs. The Competition

Export

Metric	Phio Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$11.91M	$3.91B	$7.27B	$13.03B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-0.79	14.13	274.95	25.63
Price / Sales	N/A	1,446.16	669.16	97.27
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	0.55	15.01	10.32	6.26
Net Income	-$8.70M	-$22.82M	$3.49B	$360.12M
7 Day Performance	0.29%	-2.72%	-1.33%	-0.42%
1 Month Performance	-12.56%	-7.12%	-3.71%	-3.75%
1 Year Performance	-54.13%	29.24%	14.41%	4.84%

Phio Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHIO Phio Pharmaceuticals	4.2527 of 5 stars	$1.00 -1.9%	$14.00 +1,298.6%	-53.0%	$11.63M	N/A	N/A	6	News Coverage
HOWL Werewolf Therapeutics	2.0848 of 5 stars	$0.95 -0.8%	$4.00 +321.1%	-44.7%	$46.22M	$21M	N/A	40	News Coverage
MCRB Seres Therapeutics	3.0541 of 5 stars	$4.62 -2.3%	$17.00 +268.0%	-78.4%	$46.21M	$790K	N/A	330	Gap Down
MREO Mereo BioPharma Group	3.0118 of 5 stars	$0.29 +2.1%	$1.67 +482.8%	-81.1%	$45.51M	$500K	N/A	40
MGX Metagenomi	3.2774 of 5 stars	$1.17 -2.1%	$6.00 +415.0%	-48.2%	$44.01M	$13.56M	N/A	236	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHIO) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Phio Pharmaceuticals (PHIO) Competitors

PHIO vs. HOWL, MCRB, MREO, MGX, and ATNM

How does Phio Pharmaceuticals compare to Werewolf Therapeutics?

Summary

How does Phio Pharmaceuticals compare to Seres Therapeutics?

Summary

How does Phio Pharmaceuticals compare to Mereo BioPharma Group?

Summary

How does Phio Pharmaceuticals compare to Metagenomi?

Summary

How does Phio Pharmaceuticals compare to Actinium Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHIO vs. The Competition

Phio Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Phio Pharmaceuticals (PHIO) Competitors

PHIO vs. HOWL, MCRB, MREO, MGX, and ATNM

How does Phio Pharmaceuticals compare to Werewolf Therapeutics?

Is PHIO or HOWL more profitable?

Which has more volatility & risk, PHIO or HOWL?

Do institutionals and insiders have more ownership in PHIO or HOWL?

Which has stronger valuation and earnings, PHIO or HOWL?

Does the media favor PHIO or HOWL?

Do analysts rate PHIO or HOWL?

Summary

How does Phio Pharmaceuticals compare to Seres Therapeutics?

Does the media prefer MCRB or PHIO?

Do insiders & institutionals believe in MCRB or PHIO?

Which has more volatility and risk, MCRB or PHIO?

Which has better earnings and valuation, MCRB or PHIO?

Do analysts recommend MCRB or PHIO?

Is MCRB or PHIO more profitable?

Summary

How does Phio Pharmaceuticals compare to Mereo BioPharma Group?

Which has stronger earnings and valuation, PHIO or MREO?

Do insiders & institutionals hold more shares of PHIO or MREO?

Do analysts recommend PHIO or MREO?

Does the media prefer PHIO or MREO?

Which has more volatility and risk, PHIO or MREO?

Is PHIO or MREO more profitable?

Summary

How does Phio Pharmaceuticals compare to Metagenomi?

Do analysts prefer PHIO or MGX?

Which has more volatility & risk, PHIO or MGX?

Do insiders and institutionals have more ownership in PHIO or MGX?

Does the media favor PHIO or MGX?

Is PHIO or MGX more profitable?

Which has preferable earnings and valuation, PHIO or MGX?

Summary

How does Phio Pharmaceuticals compare to Actinium Pharmaceuticals?

Do institutionals and insiders believe in PHIO or ATNM?

Is PHIO or ATNM more profitable?

Does the media refer more to PHIO or ATNM?

Which has more volatility & risk, PHIO or ATNM?

Do analysts prefer PHIO or ATNM?

Which has higher earnings & valuation, PHIO or ATNM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHIO vs. The Competition

Phio Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools